Department of Dermatology, Venereology, and Leprology, All India Institute of Medical Sciences, Jodhpur, India.
Department of Transfusion Medicine and Blood Bank, All India Institute of Medical Sciences, Jodhpur, India.
J Cosmet Dermatol. 2021 Oct;20(10):3245-3252. doi: 10.1111/jocd.14121. Epub 2021 Apr 28.
Platelet-rich plasma (PRP) has been found to be effective in treating periorbital hyperpigmentation (POH). PRP prepared by double-spin (DS) method and activated by calcium has been used conventionally. PRP can be prepared by single spin (SS) and activated at low temperature (novel method), but the evidence is limited.
To compare the novel and conventional PRP in the treatment of periorbital hyperpigmentation.
We selected 21 patients of POH and randomly divided the face into two halves. One-half of the face (group A) was treated with novel PRP (SS and low-temperature activation). The other half (group B) was treated with conventional PRP (DS and calcium activation). A total of 3 PRP injections were given at 4 weekly intervals. Patients were observed and assessed on 12 week by photography, dermoscopy, visual analog scale (VAS) score, and Dermatology life quality index (DLQI). Platelet counts and growth factors were assessed in PRP.
Mean platelet count in novel and conventional PRP was 7.41 ± 1.76 lacs and 8.17 ± 2.23 lacs (p = 0.348). Mean photographic and dermoscopic assessment at the end of the study in group A and group B was 52.33 ± 6.468 and 53.14 ± 6.99 (p = 0.151). Change in VAS in groups A and B was 3.85 ± 1.27 and 3.90 ± 1.04 (p = 0.895). Levels of various growth factors assessed by ELISA did not differ significantly. There was significant decline in DLQI.
The novel method is not inferior to conventional method of PRP in the treatment of periorbital hyperpigmentation.
富血小板血浆（PRP）已被证明可有效治疗眶周色素沉着过度（POH）。传统上使用双旋（DS）方法制备并通过钙激活的 PRP。PRP 也可以通过单旋（SS）和低温（新方法）来制备，但证据有限。
比较新型和传统 PRP 在眶周色素沉着过度治疗中的效果。
我们选择了 21 例 POH 患者，并将面部随机分为两半。一半脸（A 组）用新型 PRP（SS 和低温激活）治疗。另一半脸（B 组）用传统 PRP（DS 和钙激活）治疗。每 4 周注射 3 次 PRP。在第 12 周通过拍照、皮肤镜检查、视觉模拟量表（VAS）评分和皮肤病生活质量指数（DLQI）进行观察和评估。评估 PRP 中的血小板计数和生长因子。
新型和传统 PRP 中的平均血小板计数分别为 7.41±1.76 万和 8.17±2.23 万（p=0.348）。研究结束时 A 组和 B 组的平均摄影和皮肤镜评估分别为 52.33±6.468 和 53.14±6.99（p=0.151）。A 组和 B 组的 VAS 变化分别为 3.85±1.27 和 3.90±1.04（p=0.895）。通过 ELISA 评估的各种生长因子水平没有显著差异。DLQI 显著下降。
新型 PRP 方法在治疗眶周色素沉着过度方面并不逊于传统方法。
